Petros Family Wealth LLC Takes Position in Humacyte, Inc. (NASDAQ:HUMA)

Petros Family Wealth LLC bought a new stake in Humacyte, Inc. (NASDAQ:HUMA) during the fourth quarter, according to its most recent disclosure with the SEC. The institutional investor bought 10,000 shares of the company’s stock, valued at approximately $50,000.

Several other hedge funds have also bought and sold shares of the company. Vontobel Holding Ltd. acquired a new position in shares of Humacyte in the fourth quarter valued at $50,000. Brookstone Capital Management bought a new stake in shares of Humacyte during the 4th quarter worth about $56,000. ACT Wealth Management LLC acquired a new position in Humacyte in the 4th quarter valued at about $57,000. HighTower Advisors LLC bought a new position in Humacyte in the 4th quarter valued at about $66,000. Finally, KLP Kapitalforvaltning AS acquired a new stake in Humacyte during the fourth quarter worth approximately $99,000. 44.71% of the stock is currently owned by institutional investors and hedge funds.

Humacyte Price Performance

Shares of NASDAQ HUMA opened at $1.53 on Friday. The business has a fifty day moving average price of $2.87 and a two-hundred day moving average price of $4.17. The stock has a market capitalization of $221.61 million, a PE ratio of -1.14 and a beta of 1.62. Humacyte, Inc. has a fifty-two week low of $1.15 and a fifty-two week high of $9.97.

Humacyte (NASDAQ:HUMA) last posted its quarterly earnings results on Friday, March 28th. The company reported ($0.16) EPS for the quarter, beating analysts’ consensus estimates of ($0.23) by $0.07. The company had revenue of $7.23 million during the quarter, compared to analyst estimates of $0.64 million. On average, equities analysts expect that Humacyte, Inc. will post -1.27 EPS for the current year.

Insider Activity

In other Humacyte news, Director Kathleen Sebelius purchased 50,000 shares of the firm’s stock in a transaction dated Tuesday, April 8th. The shares were bought at an average price of $1.32 per share, for a total transaction of $66,000.00. Following the purchase, the director now owns 91,207 shares in the company, valued at approximately $120,393.24. This trade represents a 121.34 % increase in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this hyperlink. Corporate insiders own 11.20% of the company’s stock.

Wall Street Analyst Weigh In

A number of equities analysts have recently weighed in on HUMA shares. Benchmark reiterated a “buy” rating on shares of Humacyte in a research note on Thursday, February 27th. HC Wainwright reiterated a “buy” rating and set a $15.00 price objective on shares of Humacyte in a research report on Wednesday, March 12th. Finally, D. Boral Capital reissued a “buy” rating and issued a $25.00 target price on shares of Humacyte in a research report on Wednesday, March 26th. One investment analyst has rated the stock with a hold rating, six have given a buy rating and one has assigned a strong buy rating to the company. According to data from MarketBeat, the stock has an average rating of “Buy” and a consensus price target of $13.71.

Humacyte Profile

Humacyte, Inc engages in the development and manufacture of off-the-shelf, implantable, and bioengineered human tissues for the treatment of diseases and conditions across a range of anatomic locations in multiple therapeutic areas. The company using its proprietary and scientific technology platform to engineer and manufacture human acellular vessels (HAVs) to be implanted into patient without inducing a foreign body response or leading to immune rejection.